phase readout
saveNCT07234864: Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.
ACTIVE_NOT_RECRUITINGupdated 1d ago
community read0 votes
Sponsor: Eilean Therapeutics. Phase: PHASE1. Conditions: Type 2 Diabetes
view source ↗
comments(0)
5-min edit window · permanent after that